"10.1371_journal.pone.0109652","plos one","2014-10-16T00:00:00Z","Qian Qiu; Yan Li; Xiao-wan Duan; Li-kun Yang; Yu Chen; Hui Li; Li Wang; Zhong-ping Duan","Dept of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China; Liver center, Beijing You'an Hospital of Capital Medical University, Beijing, China","Conceived and designed the experiments: LW ZPD HL. Analyzed the data: QQ. Wrote the paper: QQ. Retrieved the electronic data: YL XWD LKY YC. Reviewed the manuscript: QQ YL XWD LKY YC HL LW ZPD.","This study was supported by the Ministry of National Science and Technology of China (2012ZX10004904), Bristol-Myers Squibb Company (AI463-961), Beijing Municipal and Technology Commission (Z131100004613030), and Innovative Foundation of Beijing Union Medical College. Although some funding we received was from a commercial source \"Bristol-Myers Squibb Company\", which is the manufacturer of BARACLUDE (entecavir), one of the antiviral agents studied in our study for research grants, this does not alter our adherence to PLOS ONE policies on sharing data and materials. Also, the authors have not signed an agreement with Bristol-Myers Squibb Company of the research reported in the contribution that prevents them from publishing both positive and negative results or that forbids them from publishing this research without the prior approval of the sponsor. ZPD and LW have received research support from Bristol-Myers Squibb. QQ, YL, XWD, LKY, YC and HL have no conflicts.","2014","10","Qian Qiu","QQ",8,TRUE,3,NA,1,1,TRUE,TRUE,FALSE,0,NA,FALSE
